Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Pharmacokinetics and safety of indacaterol and glycopyrronium (IND/GLY) following repeated once daily inhalation from a fixed-dose combination in healthy Chinese subjects
.

Ren S, Sechaud R, Su Z, Tillmann HC, Hara H, Tan X, Hou J, Woessner R, Zhao R.

Int J Clin Pharmacol Ther. 2017 Feb;55(2):147-155. doi: 10.5414/CP202640.

PMID:
27841152
2.

Population pharmacokinetics of IND/GLY (indacaterol/glycopyrronium) in COPD patients.

Demin I, Bartels C, Graham G, Bieth B, Gautier A, Tillmann HC, Sechaud R.

Int J Clin Pharmacol Ther. 2016 Jun;54(6):405-15. doi: 10.5414/CP202558.

PMID:
27049057
3.

Social huddling and physiological thermoregulation are related to melanism in the nocturnal barn owl.

Dreiss AN, Séchaud R, Béziers P, Villain N, Genoud M, Almasi B, Jenni L, Roulin A.

Oecologia. 2016 Feb;180(2):371-81. doi: 10.1007/s00442-015-3491-3. Epub 2015 Nov 9.

PMID:
26552377
4.

Pharmacokinetics of Glycopyrronium Following Repeated Once-Daily Inhalation in Healthy Chinese Subjects.

Sechaud R, Machineni S, Tillmann HC, Hara H, Tan X, Zhao R, Ren S, Hou J.

Eur J Drug Metab Pharmacokinet. 2016 Dec;41(6):723-731.

PMID:
26428357
5.

Glycopyrronium does not affect QT interval in healthy subjects: a randomized, three- period, cross-over, placebo- and positive-controlled study.

Drollmann A, Sechaud R, Pal P, Hara H, Uziel-Fusi S, Winkle P.

Int J Clin Pharmacol Ther. 2014 Sep;52(9):739-45. doi: 10.5414/CP202096.

PMID:
24986094
6.

Effect of dual bronchodilation with QVA149 on cardiac safety in healthy volunteers.

Drollmann A, Brown M, Sechaud R, Perry S, Hara H, Jones I, Febbraro S.

Int J Clin Pharmacol Ther. 2014 May;52(5):369-80. doi: 10.5414/CP202034.

PMID:
24569129
7.

Effect of cimetidine, a model drug for inhibition of the organic cation transport (OCT2/MATE1) in the kidney, on the pharmacokinetics of glycopyrronium.

Dumitras S, Sechaud R, Drollmann A, Pal P, Vaidyanathan S, Camenisch G, Kaiser G.

Int J Clin Pharmacol Ther. 2013 Oct;51(10):771-9. doi: 10.5414/CP201946.

PMID:
24040847
8.

Determination of the pharmacokinetics of glycopyrronium in the lung using a population pharmacokinetic modelling approach.

Bartels C, Looby M, Sechaud R, Kaiser G.

Br J Clin Pharmacol. 2013 Dec;76(6):868-79. doi: 10.1111/bcp.12118.

9.

Pharmacokinetics of multiple inhaled NVA237 doses in patients with chronic obstructive pulmonary disease (COPD).

Sechaud R, Renard D, Zhang-Auberson L, Motte Sde L, Drollmann A, Kaiser G.

Int J Clin Pharmacol Ther. 2012 Feb;50(2):118-28.

PMID:
22257577
10.

Early clinical development of artemether-lumefantrine dispersible tablet: palatability of three flavours and bioavailability in healthy subjects.

Abdulla S, Amuri B, Kabanywanyi AM, Ubben D, Reynolds C, Pascoe S, Fitoussi S, Yeh CM, Nuortti M, Séchaud R, Kaiser G, Lefèvre G.

Malar J. 2010 Sep 3;9:253. doi: 10.1186/1475-2875-9-253.

11.

Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state.

Waldmeier F, Bruin GJ, Glaenzel U, Hazell K, Sechaud R, Warrington S, Porter JB.

Drug Metab Dispos. 2010 May;38(5):808-16. doi: 10.1124/dmd.109.030833. Epub 2010 Jan 22.

PMID:
20097723
12.

Deferasirox does not induce QT/QTc-prolongation in healthy subjects.

Sechaud R, Dumortier T, Balez S.

Int J Clin Pharmacol Ther. 2009 May;47(5):321-7.

PMID:
19473594
13.

Absence of an effect of a single-dose deferasirox on the steady-state pharmacokinetics of digoxin.

Sechaud R, Robeva A, Belleli R, Balez S.

Int J Clin Pharmacol Ther. 2008 Oct;46(10):519-26.

PMID:
18826866
14.

Absolute oral bioavailability and disposition of deferasirox in healthy human subjects.

Séchaud R, Robeva A, Belleli R, Balez S.

J Clin Pharmacol. 2008 Aug;48(8):919-25. doi: 10.1177/0091270008320316. Epub 2008 May 28.

PMID:
18508948
15.

Effect of food, type of food, and time of food intake on deferasirox bioavailability: recommendations for an optimal deferasirox administration regimen.

Galanello R, Piga A, Cappellini MD, Forni GL, Zappu A, Origa R, Dutreix C, Belleli R, Ford JM, Rivière GJ, Balez S, Alberti D, Séchaud R.

J Clin Pharmacol. 2008 Apr;48(4):428-35. doi: 10.1177/0091270007313327. Epub 2008 Feb 15.

PMID:
18281442
16.

Relative bioavailability of deferasirox tablets administered without dispersion and dispersed in various drinks.

Séchaud R, Dutreix C, Balez S, Pommier F, Dumortier T, Morisson S, Brun E.

Int J Clin Pharmacol Ther. 2008 Feb;46(2):102-8.

PMID:
18218291
17.

Enteric-coated mycophenolate sodium provides higher mycophenolic acid predose levels compared with mycophenolate mofetil: implications for therapeutic drug monitoring.

Budde K, Tedesco-Silva H, Pestana JM, Glander P, Neumayer HH, Felipe CR, Machado PP, Sechaud R, Schmouder R.

Ther Drug Monit. 2007 Jun;29(3):381-4.

PMID:
17529899
18.

Pharmacokinetics and variability of mycophenolic acid from enteric-coated mycophenolate sodium compared with mycophenolate mofetil in de novo heart transplant recipients.

Hummel M, Yonan N, Ross H, Miller LW, Sechaud R, Balez S, Koelle EU, Gerosa G; ERL 2401 Study Group.

Clin Transplant. 2007 Jan-Feb;21(1):18-23.

PMID:
17302587
19.

Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major.

Galanello R, Piga A, Forni GL, Bertrand Y, Foschini ML, Bordone E, Leoni G, Lavagetto A, Zappu A, Longo F, Maseruka H, Hewson N, Sechaud R, Belleli R, Alberti D.

Haematologica. 2006 Oct;91(10):1343-51.

20.

Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.

Piga A, Galanello R, Forni GL, Cappellini MD, Origa R, Zappu A, Donato G, Bordone E, Lavagetto A, Zanaboni L, Sechaud R, Hewson N, Ford JM, Opitz H, Alberti D.

Haematologica. 2006 Jul;91(7):873-80.

21.

Randomized calcineurin inhibitor cross over study to measure the pharmacokinetics of co-administered enteric-coated mycophenolate sodium.

Kaplan B, Meier-Kriesche HU, Minnick P, Bastien MC, Sechaud R, Yeh CM, Balez S, Picard F, Schmouder R.

Clin Transplant. 2005 Aug;19(4):551-8.

PMID:
16008604
22.
23.

Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial.

Nisbet-Brown E, Olivieri NF, Giardina PJ, Grady RW, Neufeld EJ, Séchaud R, Krebs-Brown AJ, Anderson JR, Alberti D, Sizer KC, Nathan DG.

Lancet. 2003 May 10;361(9369):1597-602.

PMID:
12747879
24.

Bioequivalence study of a valsartan tablet and a capsule formulation after single dosing in healthy volunteers using a replicated crossover design.

Séchaud R, Graf P, Bigler H, Gruendl E, Letzkus M, Merz M.

Int J Clin Pharmacol Ther. 2002 Jan;40(1):35-40.

PMID:
11837381
25.

Determination of a new oral iron chelator, ICL670, and its iron complex in plasma by high-performance liquid chromatography and ultraviolet detection.

Rouan MC, Marfil F, Mangoni P, Séchaud R, Humbert H, Maurer G.

J Chromatogr B Biomed Sci Appl. 2001 May 5;755(1-2):203-13.

PMID:
11393706
26.

Estimation of glomerular filtration rate by sinistrin clearance using various approaches.

Buclin T, Sechaud R, Bertschi AP, Decosterd LA, Belaz N, Appenzeller M, Burnier M, Biollaz J.

Ren Fail. 1998 Mar;20(2):267-76.

PMID:
9574452
27.

Sinistrin clearance for determination of glomerular filtration rate: a reappraisal of various approaches using a new analytical method.

Buclin T, Pechère-Bertschi A, Séchaud R, Décosterd LA, Munafo A, Burnier M, Biollaz J.

J Clin Pharmacol. 1997 Aug;37(8):679-92.

PMID:
9378840
28.

Determination of the polyfructosan sinistrin in biological fluids by HPLC with electrochemical detection.

Séchaud R, Décosterd LA, Pechère-Bertschi A, Biollaz J, Kesselring UW.

J Pharm Biomed Anal. 1996 Feb;14(4):483-90.

PMID:
8729648
29.

[Multicenter study on the litholytic effect of ursodeoxycholic acid. 30 cases].

Voirol M, Stalder GA, Fasel J, Séchaud R, Desbaillets LG, Kapp F, Krieg P, Aenishänslin HW, Wyss G.

Schweiz Med Wochenschr. 1983 Apr 30;113(17):643-5. French.

PMID:
6346484
30.

[The value of colonoscopy].

Séchaud R.

Rev Med Suisse Romande. 1983 Mar;103(3):231-4. French. No abstract available.

PMID:
6857076
31.

[Radio-immunologic measurement of trypsin in chronic pancreatitis. Preliminary results].

Gobelet C, Bambule J, Felber JP, Magnenat P, Séchaud R.

Schweiz Med Wochenschr. 1978 Dec 2;108(48):1902-4. French. No abstract available.

PMID:
715430
32.

[Prognostic value of endoscopic investigation in gastric cancer (author's transl)].

Gonvers JJ, Realini S, Arnold J, Birchler R, Capitaine Y, Fasel J, Fontolliet C, Loup P, Séchaud R, Hofstetter JR.

Schweiz Rundsch Med Prax. 1977 Dec 6;66(49):1585-90. French. No abstract available.

PMID:
928316
33.

Extrapancreatic effect of glibenclamide: stimulation of duodenal insulin-releasing activity (DIRA) in man.

Zermatten A, Heptner W, Delaloye B, Séchaud R, Felber JP.

Diabetologia. 1977 Apr;13(2):85-8.

PMID:
404206
34.

[Treatment of ascites by ultrafiltration and reinjection of the proteins].

Séchaud R, Figueroa E, Magnenat P.

Schweiz Med Wochenschr. 1975 Dec 13;105(50):1721-4. French.

PMID:
1215967
35.

[Silicosis and diaphragmatic paralysis].

Séchaud R, Gardiol D.

Schweiz Med Wochenschr. 1969 Aug 30;99(35):1249-51. French. No abstract available.

PMID:
5351146

Supplemental Content

Loading ...
Support Center